In a research note released Thursday, J.P. Morgan analyst Cory Kasimov reiterated a Neutral rating on shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP), after the company released its third-quarter financial results and provided update on its clinical progress.

Kasimov noted, “Not much new came from the report. While we acknowledge the interesting theoretical long-term potential of ZIOP’s approach to CAR-Ts, programs have yet to enter the clinic (several expected to start trials in 2015/2016), and we await more details/proof of concept to better assess the ultimate value.”

The analyst highlighted the key upcoming events for the company, “ZIOP expects to present initial data from the Phase 2 trial of the Ad-RTS-hIL-12 in GBM at the Society for NeuroOncology meeting (Nov 19-22, San Antonio) and Phase 1b/2data in breast cancer at the San Antonio Breast Cancer Symposium (Dec 8- 12, San Antonio). Several CAR-T products are expected to enter the clinic in 2015/2016; three INDs are currently ongoing from MDA (on which we will get updates at ASH), and the company plans to submit an IND for a CAR-T product in a myeloid malignancy in late 2015 or early 2016. The company has previously indicated that solid tumor CAR-Ts and allogenic (off-the-shelf) CARTs are expected to enter the clinic in 2016.”

According to, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Cory Kasimov has a total average return of 4.4% and a 58.1% success rate. Kasimov is ranked #715 out of 3816 analysts.

Out of the 4 analysts polled by TipRanks, 3 rate Ziopharm Oncology stock a Hold, while 1 rates the stock a Buy. With a return potential of 10%, the stock’s consensus target price stands at $13.67.